Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunic ( (IMUX) ) has issued an update.
On April 28, 2026, Immunic announced the appointment of veteran neurology drug developer Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, effective April 24, 2026, succeeding co-founder Andreas Muehler, M.D., M.B.A., who will remain as a consultant. The move brings deep multiple sclerosis regulatory and late-stage development expertise to support the pivotal phase 3 ENSURE trials and potential commercialization of vidofludimus calcium in relapsing and primary progressive MS.
Panzara’s track record in securing global approvals for major MS drugs at Sanofi Genzyme and Biogen underscores Immunic’s push to transform into a fully integrated commercial-stage company as it nears key phase 3 readouts. As part of his recruitment, he received options to purchase 300,000 shares under an inducement equity plan, highlighting the strategic importance of his role for shareholders and the company’s long-term MS franchise.
The most recent analyst rating on (IMUX) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.
Spark’s Take on IMUX Stock
According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large losses, and persistent cash burn with negative equity). Offsetting this, corporate events are constructive (Nasdaq compliance regained and substantial financing), while technicals are mixed and valuation metrics are unfavorable due to ongoing losses and no dividend.
To see Spark’s full report on IMUX stock, click here.
More about Immunic
Immunic, Inc., listed on Nasdaq as IMUX, is a late-stage biotechnology company developing novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium, in phase 3 trials for relapsing multiple sclerosis. The pipeline also includes earlier-stage candidates IMU-856 and IMU-381 targeting neurodegenerative, chronic inflammatory and autoimmune-related conditions, positioning Immunic in the competitive multiple sclerosis and neuroinflammation markets.
Average Trading Volume: 395,368
Technical Sentiment Signal: Sell
Current Market Cap: $1.2B
For detailed information about IMUX stock, go to TipRanks’ Stock Analysis page.